Sulfin Special Precautions

As with all pyrazole compounds, patients receiving Sulfin should be kept under close medical supervision and periodic blood counts are recommended. It may be administered with care to patients with a history of healed peptic ulcer.
Recent reports have indicated that Sulfin potentiates the action of certain sulfonamides, such as sulfadiazine and sulfisoxazole. In addition, other pyrazole compounds (phenylbutazone) have been observed to potentiate the hypoglycemic sulfonylurea agents, as well as insulin. In view of these observations, it is suggested that Sulfin be used with caution in conjunction with sulfa drugs, the sulfonylurea hypoglycemic agents and insulin.
Because Sulfin is a potent uricosuric agent, it may precipitate urolithiasis and renal colic, especially in the initial stages of therapy. For this reason, an adequate fluid intake and alkalinization of the urine are recommended. In cases with significant renal impairment, periodic assessment of renal function is indicated. Occasional cases of renal failure have been reported; but a cause-and-effect relationship has not always been clearly established.
Salicyclates antagonize the uricosuric action of Sulfin and for this reason their concomitant use is contraindicated in gouty arthritis.
Sulfin may accentuate the action of coumarin-type anticoagulants and further depress prothrombin activity when these medications are employed simultaneously.
NOTE: Sulfin has minimal anti-inflammatory effect and is not intended for the relief of an acute attack of gout. In the initial stages of therapy, because of the marketed ability of Sulfin to mobilize urate, acute attacks of gouty arthritis may be precipitated.